
Lirafugratinib + LITESPARK011
OncoPharm
00:00
Lenvatinib Plus Belzutifan In Advanced RCC
John Bazar introduces the FDA approval and LITESPARK-011 design evaluating lenvatinib plus belzutifan after PD-1 or PD-L1 therapy in advanced clear-cell RCC.
Play episode from 05:50
Transcript


